Diagnostic Validity Comparison Between Criteria Based on CSF Alzheimer's Disease Biomarkers

Am J Alzheimers Dis Other Demen. 2017 Mar;32(2):101-107. doi: 10.1177/1533317516688298.

Abstract

Aim: To compare the diagnostic validity of NIA-AA criteria, for AD CSF biomarkers, with our own new criteria.

Materials and methods: Between 2008 and 2011, 170 patients with Mild Cognitive Impairment (MCI) were included. CSF levels of Aβ1-42, T-tau, P-tau181, and ratios of T-tau/Aβ1-42 and P-tau181/Aβ1-42 were analyzed. In our criteria, we considered 3 or more abnormal variables indicative of a high likelihood of MCI due to AD.

Results: After a clinical follow-up of 4.5 ± 1.2 years, 44 patients remained stable, 95 developed AD, 15 other forms of dementia, 7 died and 9 received other diagnoses. Using the NIA-AA criteria and our own criteria, the diagnostic validity of the CSF biomarkers was 58% versus 85%, specificity 84% versus 72%, PPV 82% versus 79% and NPV 61% versus 79%.

Conclusion: The inclusion of the ratios in diagnostic criteria increases sensitivity and NPV for the diagnosis of MCI due to AD.

Keywords: Alzheimer’s disease; CSF; biomarkers; diagnostic validity; mild cognitive impairment; ratios.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / cerebrospinal fluid*
  • Amyloid beta-Peptides / cerebrospinal fluid*
  • Biomarkers / cerebrospinal fluid*
  • Cognitive Dysfunction / cerebrospinal fluid*
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • National Institute on Aging (U.S.) / standards
  • Peptide Fragments / cerebrospinal fluid*
  • Practice Guidelines as Topic / standards
  • Reproducibility of Results
  • Sensitivity and Specificity
  • United States
  • tau Proteins / cerebrospinal fluid*

Substances

  • Amyloid beta-Peptides
  • Biomarkers
  • Peptide Fragments
  • amyloid beta-protein (1-42)
  • tau Proteins